The value of hepatobiliary phase in EOB-MRI in predicting hypervascularization outcome of non-hypervascular hypointense lesions in high-risk patients for hepatocellular carcinoma
Feiqian Wang(First Affiliated Hospital of Xi'an Jiaotong University), Shin Maeda(University of Tokyo Hospital), Satoshi Moriya(Yokohama City University Medical Center), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Masahiro Okada, Masako Otani(Mita Hospital), Akito Nozaki(Yokohama City University Medical Center), Hiromi Nihonmatsu(Yokohama City University Medical Center), Hiroyuki Fukuda(Yokohama City University Medical Center), Litao Ruan(First Affiliated Hospital of Xi'an Jiaotong University), Wen Luo(Xijing Hospital), Masayuki Nakano(Nihon University), Norihiro Koizumi(University of Electro-Communications), Yoshiaki Inayama(Yokohama City University Medical Center), Katsuaki Ogushi(Yokohama City University Medical Center)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283